On May 13, 2026, Takeda Pharmaceutical Company used its full-year earnings presentation to disclose that its multiyear transformation program will eliminate roughly 4,500 roles during fiscal year 2026. That is about 9% of the company's 49,000-person global workforce and the largest single workforce reduction announcement in Takeda's history. Japan's largest drugmaker said the program will generate around 170 billion yen (about $1.07 billion) in restructuring costs this fiscal year and deliver gross savings of about 100 billion yen ($633 million) in FY2026, building toward roughly $1.26 billion in annualized savings by 2028.
The 634 US cuts already filed via Massachusetts WARN notices in March, including roughly 250 in Cambridge, are part of this 4,500 total rather than additive to it. Takeda framed the May 13 number as the full-year picture for FY2026 across centralized corporate functions, reduced management layers, and process simplification.
The announcement lands as Takeda prepares for a leadership transition next month, with an incoming CEO inheriting a company that has spent more than a year working through the revenue cliff from the loss of US exclusivity on ADHD treatment Vyvanse. Outgoing CEO Christophe Weber positioned the transformation as the runway clear-out before three near-term launches: narcolepsy treatment oveporexton, polycythemia vera candidate rusfertide, and psoriasis medicine zasocitinib.
Takeda used the phrase "new era" in its own release on the May 13 announcement, signaling that the company is treating this as a single multiyear program rather than a sequence of one-off WARN filings. That is a meaningful distinction for employees and investors trying to size the total exposure: the Cambridge cuts in March were the first visible piece of an already-decided 4,500-job plan, not a standalone event.
The Cambridge, Massachusetts cuts disclosed in March affect 634 US staffers, with roughly 250 concentrated at the Cambridge R&D campus. The rest of the 4,500 total will spread across Japan headquarters functions, Europe commercial operations, and regional shared-service centers, with Takeda describing the focus as centralization of duplicated corporate functions and removal of management layers.
Pharma cost programs of this size are normally announced after a major patent loss or a failed pipeline asset. Takeda's case is closer to the former: Vyvanse generics arrived in late 2023 and the revenue impact has compounded across 2024 and 2025. The $1.26 billion annualized savings target by 2028 is roughly 4% of Takeda's annual revenue base, putting the program in the same general weight class as Pfizer's and Bristol-Myers Squibb's recent restructurings. Watch for whether Takeda's three FY2026/2027 launches deliver the revenue ramp the transformation is sized for, and whether further site closures appear in the company's Japan or European operations once the incoming CEO sets a specific footprint plan.